Eventide Asset Management LLC Has $33.67 Million Holdings in Kestra Medical Technologies, Ltd. $KMTS

Eventide Asset Management LLC lifted its holdings in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 5.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,269,651 shares of the company’s stock after acquiring an additional 65,288 shares during the quarter. Eventide Asset Management LLC owned approximately 2.18% of Kestra Medical Technologies worth $33,671,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brown Brothers Harriman & Co. boosted its holdings in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Kestra Medical Technologies by 7.3% in the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after acquiring an additional 874 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies in the 4th quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after acquiring an additional 1,392 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on KMTS shares. BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. The Goldman Sachs Group reduced their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $27.40.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider owned 334,786 shares in the company, valued at approximately $7,017,114.56. The trade was a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 45,000 shares of company stock worth $919,050. Insiders own 3.60% of the company’s stock.

Kestra Medical Technologies Stock Up 3.5%

NASDAQ:KMTS opened at $20.85 on Friday. The stock’s fifty day moving average price is $20.70 and its two-hundred day moving average price is $23.10. Kestra Medical Technologies, Ltd. has a 52-week low of $13.25 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -5.27 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million for the quarter. The business’s quarterly revenue was up 62.7% on a year-over-year basis. On average, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.